Last reviewed · How we verify
NCT06650774
Comparison of the Efficacy of Pirfenidone and Nintedanipine in Pulmonary Fibrosis
trial in Idiopathic Pulmonary Fibrosis (IPF) in 152 participants. Completed in 30 September 2024.
30 August 2024
Quick facts
| Lead sponsor | Karadeniz Technical University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 152 |
| Start date | 15 June 2024 |
| Primary completion | 30 August 2024 |
| Estimated completion | 30 September 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- Idiopathic Pulmonary Fibrosis (IPF) — all drugs for Idiopathic Pulmonary Fibrosis (IPF) →
Sponsor
Karadeniz Technical University
Who can join
18 and older, any sex, with Idiopathic Pulmonary Fibrosis (IPF). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to compare the effects of pirfenidone and nintedanib on lung function and radiologic findings in fibrotic lung diseases. The main question it aims to answer is: • Do these two drugs have equivalent effects on progression in patients with pulmonary fibrosis? If there is a comparison group: The investigators will compare patients with pulmonary fibrosis receiving pirfenidone with patients with pulmonary fibrosis receiving nintedanip. The investigators will compare patients with pulmonary fibrosis receiving pirfenidone and patients with pulmonary fibrosis receiving nintedanip. Pulmonary function test parameters at 3rd, 6th, 9th and 12th months and differences of 6 MWT parameters compared to baseline will be compared between the two groups.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06650774
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Idiopathic Pulmonary Fibrosis (IPF)
Currently open trials in the same condition.
- NCT07482917 — Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial · NA · recruiting
- NCT07486206 — Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial · NA · recruiting
- NCT06968845 — A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis · Phase 2 · recruiting
- NCT07466420 — Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases. · NA · recruiting
- NCT07464912 — A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic · Phase 3 · recruiting
Other Karadeniz Technical University trials
Trials by the same sponsor.
- NCT07526779 — Motivational Interviewing on Loneliness Level, Activities of Daily Living, and Quality of Life in Elderly · NA · not yet recruiting
- NCT07448168 — Effect of Standardized Patient Simulation on Nursing Students' Assessment, Diagnosis Skills, and Experiences · NA · not yet recruiting
- NCT07435233 — Different Reality Simulation Education Methods on Nursing Students · NA · active not recruiting
- NCT07238348 — Analgesic Effectiveness of SPSIPB Versus Thoracic Epidural and Systemic Opioid Analgesia After VATS (SPSIPB-VATS) · not yet recruiting
- NCT07297498 — The Effect of Simulation-based Education Within the Framework of the Clinical Judgment Model on Nursing Students' Clinic · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06650774 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Karadeniz Technical University
- Last refreshed: 21 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06650774.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing